Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (3927)	8/26/2001 11:16:52 AM
From: Hank	Respond to of 5582

I'm curious Danny Boy. Are all these negative numbers in line with your expert "estimates"? 2001 2000 2001 2000 ($000's) 2nd Qtr 2nd Qtr YTD YTD Net Sales $ 1,373 $ 1,814 $ 7,846 $ 4,917 Cost of Sales 482 610 2,096 1,751 Gross Profit 891 1,204 5,750 3,166 Operating Expenses 3,626 1,655 8,091 6,470 Research and Development 183 144 234 184 Income (Loss) From Operations (2,918) (595) (2,575) (3,489) Interest and Other Income 37 81 65 172 Interest Expense 39 2 65 412 Income (Loss) Before Taxes and Minority Interest (2,920) (516) (2,575) (3,728) Income Tax Expense - - - 9 Minority Interest in Gel Tech LLC (986) (87) (744) (1,087) Net Income (Loss) From Continuing Operations (1,934) (429) (1,832) (2,649) Net Income (Loss) From Discontinued Operations (368) (487) (124) (983) Preferred Stock Dividends - - - 12 Net Income (Loss) to Common Shareholders $ (2,302) $ (916) $ (1,956) $ (3,644) Net Income (Loss) per Share: Continuing Operations $ (0.21) $ (0.05) $ (0.20) $ (0.30) Discontinued Operations $ (0.04) $ (0.05) $ (0.01) $ (0.11) Average Shares Outstanding (millions) 9.2 8.9 9.2 8.8 At least they're consistent! LOL!!!

To: DanZ who wrote (3927)	9/4/2001 3:27:55 PM
From: rli123	Respond to of 5582

Tuesday September 4, 1:26 pm Eastern Time Press Release SOURCE: Gum Tech International, Inc. Gum Tech Appoints New Member To Board of Directors PHOENIX, Sept. 4 /PRNewswire/ -- Gum Tech International, Inc. (Nasdaq: GUMM - news) today announced the appointment of Mr. William C. Egan to its Board of Directors. The appointment became effective on August 30, 2001. ``As Gum Tech considers various strategic business alternatives, post the Wrigley transaction, Mr. Egan's extensive management and marketing background in the healthcare industry will benefit Gum Tech tremendously,'' stated Carl Johnson, Gum Tech's President and Chief Executive Officer. ``His experience in domestic and international distribution, marketing and business operations are a further enhancement to our already diverse board of business executives.'' Mr. Egan was employed with Johnson & Johnson for over 23 years where he most recently held the position of Executive Vice President of Global Skin Care. Additional positions with Johnson & Johnson included Franchise Group Chairman, Consumer Products Worldwide, President of Baby Products and Chairman of Windsor Minerals, Inc. (a division of Johnson & Johnson). Additional employment included President of Arm & Hammer Consumer Products (a division of Church & Dwight Co., Inc.) and Group Product Director, Tylenol Products for the McNeil Consumer Products Company. Mr. Egan currently serves as Chairman of the Board of Directors of the Cosmetic, Toiletry, and Fragrance Association. He is also a Board member of the U.S. Dermatologics, J. L. Kellogg Graduate School of Management, the Princeton Medical Center, and Westminster School. Mr. Egan graduated from Trinity College and received a Master of Business Administration from the Northwestern University, J. L. Kellogg Graduate School of Management. Mr. Ed Faber, Chairman of the Board of Directors stated, ``Mr. Egan represents a further strengthening of Gum Tech's Board; an effort which began in September 2000. The Gum Tech Board of Directors now represents a combined 180 years of successful general management experience and is focused on guiding the Company through this critical transition period.'' Mr. Egan will fill a vacancy on the Board created by the resignation of Mr. William Boone effective September 1, 2001. Mr. Faber stated, ``On behalf of the shareholders of the Company, I want to thank Mr. Boone for his many years of service and commitment to Gum Tech. He has played a key role in guiding the Company through his service on the Board.'' Gum Tech International, Inc. is an innovative nutrient and drug delivery technology company engaged in the development, manufacture and marketing of delivery systems for bioactive compounds. Gum Tech is the majority owner of Gel Tech, LLC, which markets Zicam(TM) Cold Remedy, a patented, revolutionary homeopathic remedy that significantly reduces the duration and severity of the common cold, and Zicam(TM) Allergy Relief, a homeopathic remedy designed to provide relief to allergy sufferers. In a study published in the October 2000 issue of the ENT - Ear, Nose & Throat Journal, Zicam(TM) Cold Remedy was shown to reduce the duration of the common cold by an average of 75% when taken at the onset of symptoms. For additional information, please contact Lynn Romero, Manager of Investor Relations, 602-387-5353, lromero@gum-tech.com. Gum Tech is located at 2375 East Camelback Road, Suite 500, Phoenix, AZ 85016.